CeriBell (NASDAQ:CBLL) CFO Scott Blumberg Sells 990 Shares

CeriBell, Inc. (NASDAQ:CBLL) CFO Scott Blumberg sold 990 shares of the firm’s stock in a transaction dated Tuesday, August 18th. The shares were sold at an average price of $25.00, for a total value of $24,750.00. Following the completion of the transaction, the chief financial officer owned 148,121 shares of the company’s stock, valued at $3,703,025. The trade was a 0.66% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website.

Scott Blumberg also recently made the following trade(s):

• On Wednesday, August 19th, Scott Blumberg sold 33,512 shares of CeriBell stock. The shares were sold at an average price of $25.03, for a total transaction of $838,805.36.

CeriBell Stock Performance

Shares of NASDAQ CBLL opened at $24.31 on Friday. The stock has a 50 day moving average of $19.43 and a 200-day moving average of $19.19. The company has a current ratio of 9.18, a quick ratio of 8.79 and a debt-to-equity ratio of 0.16. The company has a market capitalization of $933.02 million, a P/E ratio of -13.81 and a beta of 0.81. CeriBell, Inc. has a 12 month low of $10.85 and a 12 month high of $25.33.

CeriBell (NASDAQ:CBLL) last posted its earnings results on Monday, August 10th. The company reported ($0.51) EPS for the quarter, missing the consensus estimate of ($0.47) by ($0.04). The firm had revenue of $28.10 million during the quarter, compared to analyst estimates of $27.28 million. CeriBell had a negative net margin of 64.73% and a negative return on equity of 44.85%. As a group, equities research analysts predict that CeriBell, Inc. will post -1.96 EPS for the current year.

Wall Street Analysts Forecast Growth

A number of research analysts recently commented on CBLL shares. BTIG Research boosted their price target on CeriBell from $28.00 to $30.00 and gave the company a “buy” rating in a research note on Tuesday. Weiss Ratings upgraded shares of CeriBell from a “sell (e+)” rating to a “sell (d-)” rating in a report on Thursday, August 13th. Barclays raised CeriBell to a “neutral” rating in a research note on Tuesday. Finally, Canaccord Genuity Group increased their price objective on shares of CeriBell from $25.00 to $26.00 and gave the stock a “buy” rating in a research report on Tuesday, August 11th. One equities research analyst has rated the stock with a Strong Buy rating, four have issued a Buy rating, one has assigned a Hold rating and one has assigned a Sell rating to the company. According to MarketBeat.com, CeriBell presently has a consensus rating of “Moderate Buy” and an average target price of $22.40.

Institutional Trading of CeriBell

A number of large investors have recently added to or reduced their stakes in CBLL. Wellington Management Group LLP boosted its position in CeriBell by 5.5% during the second quarter. Wellington Management Group LLP now owns 87,698 shares of the company’s stock worth $1,706,000 after purchasing an additional 4,572 shares during the period. Formula Growth Ltd. purchased a new stake in shares of CeriBell in the second quarter worth $603,000. Bank of America Corp DE bought a new stake in shares of CeriBell during the 2nd quarter valued at about $4,619,000. PDT Partners LLC bought a new position in shares of CeriBell in the 2nd quarter worth $1,026,000. Finally, Legal & General Group Plc purchased a new stake in CeriBell during the second quarter valued at about $53,000.

CeriBell News Summary

Here are the key news stories impacting CeriBell this week:

• Positive Sentiment: BTIG raised its price target to $30 and reiterated a Buy rating, signaling confidence in CeriBell’s growth outlook. Canaccord Genuity also raised its target to $26 and maintained a Buy rating. CeriBell Stock Price Expected to Rise, BTIG Research Analyst Says
• Positive Sentiment: Institutional ownership activity was generally constructive, with several firms adding to or initiating small positions in CBLL. Barclays also upgraded the shares to Neutral, while the broader analyst consensus remains “Moderate Buy.”
• Neutral Sentiment: CeriBell’s latest quarter showed mixed results: revenue of $28.10 million exceeded estimates of $27.28 million, but adjusted EPS of negative $0.51 missed the consensus loss estimate of negative $0.47. The company remains unprofitable, with analysts expecting a full-year loss.
• Negative Sentiment: CEO Xingjuan Chao sold 31,415 shares for approximately $786,000 at an average price of $25.03, reducing her ownership by 3.83%. She also sold 2,199 shares the prior day and has made additional sales in recent months. Xingjuan Chao Sells Shares of CeriBell
• Negative Sentiment: CFO Scott Blumberg sold 33,512 shares worth approximately $839,000 and an additional 990 shares, reducing his direct holdings by about 18.45% overall. Multiple senior-executive sales near the stock’s recent highs may reinforce profit-taking concerns and help explain the stock’s decline.

CeriBell Company Profile

CeriBell Corp (NASDAQ: CBLL) is a healthcare technology company specializing in the design, manufacture and sale of automated newborn hearing screening devices. The company offers a suite of medical diagnostic tools based on otoacoustic emissions (OAE) and auditory brainstem response (ABR) technologies, enabling early detection of auditory impairments in infants. CeriBell’s solutions are used in hospitals, birthing centers and audiology clinics to support universal newborn hearing screening programs aimed at improving language development outcomes through prompt intervention.

The company’s product portfolio includes handheld and desktop screening units, proprietary software for data management, and accessories designed to streamline testing workflows.